Five Prime Therapeutics, Inc. (FPRX): Price and Financial Metrics
FPRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for FPRX is 0.05 -- better than merely 11.05% of US stocks.
- With a price/sales ratio of 134.29, Five Prime Therapeutics Inc has a higher such ratio than 96.79% of stocks in our set.
- In terms of volatility of its share price, FPRX is more volatile than 97.19% of stocks we're observing.
- Stocks that are quantitatively similar to FPRX, based on their financial statements, market capitalization, and price volatility, are KDMN, CLSN, PTCT, RMBS, and RGLS.
- FPRX's SEC filings can be seen here. And to visit Five Prime Therapeutics Inc's official web site, go to www.fiveprime.com.
FPRX Stock Price Chart Interactive Chart >
FPRX Price/Volume Stats
| Current price | $38.00 | 52-week high | $38.90 |
| Prev. close | $37.99 | 52-week low | $2.61 |
| Day low | $37.95 | Volume | 1,006,600 |
| Day high | $38.01 | Avg. volume | 1,981,352 |
| 50-day MA | $31.27 | Dividend yield | N/A |
| 200-day MA | $15.17 | Market Cap | 1.77B |
Five Prime Therapeutics, Inc. (FPRX) Company Bio
Five Prime Therapeutics discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. The company was founded in 2001 and is based in South San Francisco, California.
Latest FPRX News From Around the Web
Below are the latest news stories about Five Prime Therapeutics Inc that investors may wish to consider to help them evaluate FPRX as an investment opportunity.
Amgen Successfully Completes Acquisition Of Five Prime TherapeuticsAmgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. |
Halper Sadeh LLP Investigates the Following Mergers - TPCO, STAY, KSU, CUB, AEGN, FPRX; Shareholders Are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: |
SHAREHOLDER ALERT: WeissLaw LLP Reminds FI, SVBI, FRPX, and VKIN Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss why Amgen needs to seek out this potential growth and whether Five Prime's pipeline is worth the premium Amgen paid for it. |
Lifshitz Law Firm, P.C. Announces Investigation of FPRX, NBLX, PAND, and SHBINEW YORK, NY / ACCESSWIRE / March 21, 2021 / Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Lifshitz Law Firm, P. |
FPRX Price Returns
| 1-mo | 0.21% |
| 3-mo | 156.41% |
| 6-mo | 595.97% |
| 1-year | 1,262.01% |
| 3-year | 135.44% |
| 5-year | -22.34% |
| YTD | 123.40% |
| 2020 | 270.59% |
| 2019 | -50.65% |
| 2018 | -57.57% |
| 2017 | -56.26% |
| 2016 | 20.75% |
Continue Researching FPRX
Here are a few links from around the web to help you further your research on Five Prime Therapeutics Inc's stock as an investment opportunity:Five Prime Therapeutics Inc (FPRX) Stock Price | Nasdaq
Five Prime Therapeutics Inc (FPRX) Stock Quote, History and News - Yahoo Finance
Five Prime Therapeutics Inc (FPRX) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...